Cancer Profiling Market Report
RA01207
Cancer Profiling Market, by Technology (Immunoassays,Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays, Others), Cancer Type (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer), Biomaker Type (Genomic Biomarker, Protein Biomarker), Application (Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening, Treatment & Monitoring): Global Opportunity Analysis and Industry Forecast, 2020-2027
The global cancer profiling market is estimated to surpass $17,015.9 million by 2027, exhibiting a CAGR of 10.8% from 2020 to 2027.
The report offers thorough analysis of the global cancer profiling market by meticulously studying different aspects of the market including market dynamics, major segments, growth opportunities, regional market conditions, and leading players operating in the market.
This research report sheds a light on the current market scenario and upcoming trends & developments predicted to contribute for the global market growth during the forecast period. In addition, key market drivers and opportunities boosting the market growth are delivered in the report. Also, challenges and restraints that hold power to restrict the market growth are also offered in the report. Further, the report offers Porter’s five forces analysis of the market to elucidate factors such as bargaining power of suppliers & buyers, competitive landscape, threats of new players, and the occurrence of substitutes in the market.
The report offers future perspectives and growth outlook of the global cancer profiling market that is based on the key forces molding the market. The report provides market size and forecast by keenly evaluating each segment of the global market. Regional market breakdown of these segments is also offered in the report. The report segments the global cancer profiling market into four major regions including North America, Europe, Asia-Pacific, and LAMEA. Furthermore, these regions are sub-segmented to provide detailed panorama of the cancer profiling market across major countries in specific regions. Moreover, the report includes some of the recent developments, trends, and future opportunities in each region.
Furthermore, the report highlights the major players functioning in the global cancer profiling market. A detailed overview of top 10 players operating in the global cancer profiling market is provided in the report for understanding their status and foothold over the market share. Company profile of each player includes several data points such as short overview of the company, major company executives, company’s financial status and revenue, major business strategies implemented by company, innovative developments or initiatives taken by company to shove their position and standout among other competitors in the global cancer profiling market.
RESEARCH METHODOLOGY
Research Dive offers its clients extensive research and analysis gleaned from wide variety of factual inputs that largely includes interview with participants of the industry, reliable data & statistics, and regional intelligence. The in-house experts of the industry play a crucial role in designing analytic tools and models, tailor-made to the requests of an industry segment. The data and statistics are sterilized with these analytical tools and models, which enhances the accuracy of our advice and recommendations.
This research report is delivered by Research Dive by conducting long hours of discussions and interviews, with a broad range of stakeholders, which includes upstream and downstream participants. Our analysts have performed a mix of primary and secondary research for the market estimations and forecasts. A number of product type literatures, industry releases, annual reports, and other related documents of major participants of the industry have been reviewed, to better understand the global cancer profiling market scenario. The initial phase of our in-depth study, where we perform wide-range data mining, referring to proficient & verified data sources such as independent studies, medical journals, technical journals, releases by trade association, materials published by government & regulatory authorities, and other.
KEY MARKET BENEFITS
- The report is a compilation of detailed information, inputs from industry participants and industry experts across the value chain, and quantitative and qualitative assessment by industry analysts
- This report provides in-depth analysis of current market trends, governing factors, macro-economic indicators from 2019 to 2027 to identify & understand the prevailing opportunities and the strategic assessment of the growth of the global cancer profiling market
- The report maps the qualitative sway of various industry factors on market segments as well as geographies
- The market estimations and size provided in the report are based on a comprehensive analysis of recent & futuristic key developments in the cancer profiling market
- The growth and development strategies adopted by the prominent industry players are enlisted in the report to understand the competitive scenario of the cancer profiling market
KEY MARKET SEGMENTS
The market has been studied based on the following segments:
- Technology: Immunoassays, Next-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, In-Situ Hybridization, Microarrays, Others
- Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancer
- Biomaker Type: Genomic Biomarker, Protein Biomarker
- Application: Research, Biomarker Discovery, Personalized Medicine, Clinical Application, Diagnostics, Prognostics, Screening, Treatment & Monitoring
Region:
The global cancer profiling market is divided into North America, Europe, Asia Pacific, and LAMEA.
The above-mentioned regions are further dived in countries as follows:
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Argentina
- Saudi Arabia
- South Africa
- UAE
- Rest of LAMEA
KEY PLAYERS
The key players profiled in the report are Tempus Labs, HTG Molecular Diagnostics, Inc., Agendia, Agendia.
The report outlines the business overview including financial performance, latest strategic moves & developments, product portfolio, and SWOT analysis of the leading players of the cancer profiling market.
1. llumina, Inc.
2. QIAGEN N.V.
3. NeoGenomics Laboratories, Inc.
4. HTG Molecular Diagnostics, Inc.
5. Genomic Health Inc.
6. Caris Life Sciences
7. Helomics Corporation
8. NanoString Technologies, Inc.
9. Sysmex Corporation
10. Ribomed Biotechnologies, Inc.
11. Guardant Health, Inc.
12. Foundation Medicine
13. Roche Diagnostics
14. GenScript Biotech Corporation
15. Tempus Labs
16. Boreal Genomics Inc
17. Perthera
18. Agendia
19. Omniseq
20. Histogene X
-
1. RESEARCH METHODOLOGY
1.1. Desk Research
1.2. Real time insights and validation
1.3. Forecast model
1.4. Assumptions and forecast parameters
1.5. Market size estimation
1.5.1. Top-down approach
1.5.2. Bottom-up approach
-
2. REPORT SCOPE
2.1. Market definition
2.2. Key objectives of the study
2.3. Report overview
2.4. Market segmentation
2.5. Overview of the impact of COVID-19 on Global Cancer Profiling Market
-
3. EXECUTIVE SUMMARY
-
4. MARKET OVERVIEW
4.1. Introduction
4.2. Growth impact forces
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Market value chain analysis
4.3.1. List of raw material suppliers
4.3.2. List of manufacturers
4.3.3. List of distributors
4.4. Innovation & sustainability matrices
4.4.1. Technology matrix
4.4.2. Regulatory matrix
4.5. Porter’s five forces analysis
4.5.1. Bargaining power of suppliers
4.5.2. Bargaining power of consumers
4.5.3. Threat of substitutes
4.5.4. Threat of new entrants
4.5.5. Competitive rivalry intensity
4.6. PESTLE analysis
4.6.1. Political
4.6.2. Economical
4.6.3. Social
4.6.4. Technological
4.6.5. Environmental
4.7. Impact of COVID-19 on Cancer Profiling Market
4.7.1. Pre-covid market scenario
4.7.2. Post-covid market scenario
-
5. Cancer Profiling Market, By Lumen
5.1. Overview
5.2 Immunoassays
5.2.1 Definition, key trends, growth factors, and opportunities
5.2.2 Market size analysis, by region, 2020-2027
5.2.3 Market share analysis, by country, 2020-2027
5.3 Next-Generation Sequencing
5.3.1 Definition, key trends, growth factors, and opportunities
5.3.2 Market size analysis, by region, 2020-2027
5.3.3 Market share analysis, by country, 2020-2027
5.4 Polymerase Chain Reaction
5.4.1 Definition, key trends, growth factors, and opportunities
5.4.2 Market size analysis, by region, 2020-2027
5.4.3 Market share analysis, by country, 2020-2027
5.5 Mass Spectrometry
5.5.1 Definition, key trends, growth factors, and opportunities
5.5.2 Market size analysis, by region, 2020-2027
5.5.3 Market share analysis, by country, 2020-2027
5.6 In-Situ Hybridization
5.6.1 Definition, key trends, growth factors, and opportunities
5.6.2 Market size analysis, by region, 2020-2027
5.6.3 Market share analysis, by country, 2020-2027
5.7 Microarrays
5.7.1 Definition, key trends, growth factors, and opportunities
5.7.2 Market size analysis, by region, 2020-2027
5.7.3 Market share analysis, by country, 2020-2027
5.8 Others
5.8.1 Definition, key trends, growth factors, and opportunities
5.8.2 Market size analysis, by region, 2020-2027
5.8.3 Market share analysis, by country, 2020-2027
5.9 Research Dive Exclusive Insights
5.9.1 Market attractiveness
5.9.2 Competition heatmap
-
6. Cancer Profiling Market, By Method
6.1. Overview
6.2 Breast Cancer
6.2.1 Definition, key trends, growth factors, and opportunities
6.2.2 Market size analysis, by region, 2020-2027
6.2.3 Market share analysis, by country, 2020-2027
6.3 Lung Cancer
6.3.1 Definition, key trends, growth factors, and opportunities
6.3.2 Market size analysis, by region, 2020-2027
6.3.3 Market share analysis, by country, 2020-2027
6.4 Colorectal Cancer
6.4.1 Definition, key trends, growth factors, and opportunities
6.4.2 Market size analysis, by region, 2020-2027
6.4.3 Market share analysis, by country, 2020-2027
6.5 Prostate Cancer
6.5.1 Definition, key trends, growth factors, and opportunities
6.5.2 Market size analysis, by region, 2020-2027
6.5.3 Market share analysis, by country, 2020-2027
6.6 Melanoma Cancer
6.6.1 Definition, key trends, growth factors, and opportunities
6.6.2 Market size analysis, by region, 2020-2027
6.6.3 Market share analysis, by country, 2020-2027
6.7 Other Cancer
6.7.1 Definition, key trends, growth factors, and opportunities
6.7.2 Market size analysis, by region, 2020-2027
6.7.3 Market share analysis, by country, 2020-2027
6.8 Research Dive Exclusive Insights
6.8.1 Market attractiveness
6.8.2 Competition heatmap
-
7. Cancer Profiling Market, By Type Of Waste
7.1. Overview
7.2 Genomic Biomarker
7.2.1 Definition, key trends, growth factors, and opportunities
7.2.2 Market size analysis, by region, 2020-2027
7.2.3 Market share analysis, by country, 2020-2027
7.3 Protein Biomarker
7.3.1 Definition, key trends, growth factors, and opportunities
7.3.2 Market size analysis, by region, 2020-2027
7.3.3 Market share analysis, by country, 2020-2027
7.4 Research Dive Exclusive Insights
7.4.1 Market attractiveness
7.4.2 Competition heatmap
-
8. Cancer Profiling Market, By Resorbability
8.1. Overview
8.2 Research
8.2.1 Definition, key trends, growth factors, and opportunities
8.2.2 Market size analysis, by region, 2020-2027
8.2.3 Market share analysis, by country, 2020-2027
8.3 Biomarker Discovery
8.3.1 Definition, key trends, growth factors, and opportunities
8.3.2 Market size analysis, by region, 2020-2027
8.3.3 Market share analysis, by country, 2020-2027
8.4 Personalized Medicine
8.4.1 Definition, key trends, growth factors, and opportunities
8.4.2 Market size analysis, by region, 2020-2027
8.4.3 Market share analysis, by country, 2020-2027
8.5 Clinical Application
8.5.1 Definition, key trends, growth factors, and opportunities
8.5.2 Market size analysis, by region, 2020-2027
8.5.3 Market share analysis, by country, 2020-2027
8.6 Diagnostics
8.6.1 Definition, key trends, growth factors, and opportunities
8.6.2 Market size analysis, by region, 2020-2027
8.6.3 Market share analysis, by country, 2020-2027
8.7 Prognostics
8.7.1 Definition, key trends, growth factors, and opportunities
8.7.2 Market size analysis, by region, 2020-2027
8.7.3 Market share analysis, by country, 2020-2027
8.8 Screening
8.8.1 Definition, key trends, growth factors, and opportunities
8.8.2 Market size analysis, by region, 2020-2027
8.8.3 Market share analysis, by country, 2020-2027
8.9 Treatment & Monitoring
8.9.1 Definition, key trends, growth factors, and opportunities
8.9.2 Market size analysis, by region, 2020-2027
8.9.3 Market share analysis, by country, 2020-2027
8.10 Research Dive Exclusive Insights
8.10.1 Market attractiveness
8.10.2 Competition heatmap
9. Cancer Profiling Market, By Region
9.1 North America
9.1.1 U.S
9.1.1.1 Market size analysis, By Lumen, 2020-2027
9.1.1.2 Market size analysis, By Method, 2020-2027
9.1.1.3 Market size analysis, By Type of Waste, 2020-2027
9.1.1.4 Market size analysis, By Resorbability, 2020-2027
9.1.2 Canada
9.1.2.1 Market size analysis, By Lumen, 2020-2027
9.1.2.2 Market size analysis, By Method, 2020-2027
9.1.2.3 Market size analysis, By Type of Waste, 2020-2027
9.1.2.4 Market size analysis, By Resorbability, 2020-2027
9.1.3 Mexico
9.1.3.1 Market size analysis, By Lumen, 2020-2027
9.1.3.2 Market size analysis, By Method, 2020-2027
9.1.3.3 Market size analysis, By Type of Waste, 2020-2027
9.1.3.4 Market size analysis, By Resorbability, 2020-2027
9.1.4 Research Dive Exclusive Insights
9.1.4.1 Market attractiveness
9.1.4.2 Competition heatmap
9.2 Europe
9.2.1 Germany
9.2.1.1 Market size analysis, By Lumen, 2020-2027
9.2.1.2 Market size analysis, By Method, 2020-2027
9.2.1.3 Market size analysis, By Type of Waste, 2020-2027
9.2.1.4 Market size analysis, By Resorbability, 2020-2027
9.2.2 UK
9.2.2.1 Market size analysis, By Lumen, 2020-2027
9.2.2.2 Market size analysis, By Method, 2020-2027
9.2.2.3 Market size analysis, By Type of Waste, 2020-2027
9.2.2.4 Market size analysis, By Resorbability, 2020-2027
9.2.3 France
9.2.3.1 Market size analysis, By Lumen, 2020-2027
9.2.3.2 Market size analysis, By Method, 2020-2027
9.2.3.3 Market size analysis, By Type of Waste, 2020-2027
9.2.3.4 Market size analysis, By Resorbability, 2020-2027
9.2.4 Spain
9.2.4.1 Market size analysis, By Lumen, 2020-2027
9.2.4.2 Market size analysis, By Method, 2020-2027
9.2.4.3 Market size analysis, By Type of Waste, 2020-2027
9.2.4.4 Market size analysis, By Resorbability, 2020-2027
9.2.5 Italy
9.2.5.1 Market size analysis, By Lumen, 2020-2027
9.2.5.2 Market size analysis, By Method, 2020-2027
9.2.5.3 Market size analysis, By Type of Waste, 2020-2027
9.2.5.4 Market size analysis, By Resorbability, 2020-2027
9.2.6 Rest of Europe
9.2.6.1 Market size analysis, By Lumen, 2020-2027
9.2.6.2 Market size analysis, By Method, 2020-2027
9.2.6.3 Market size analysis, By Type of Waste, 2020-2027
9.2.6.4 Market size analysis, By Resorbability, 2020-2027
9.2.7 Research Dive Exclusive Insights
9.2.7.1 Market attractiveness
9.2.7.2 Competition heatmap
9.3 Asia-Pacific
9.3.1 China
9.3.1.1 Market size analysis, By Lumen, 2020-2027
9.3.1.2 Market size analysis, By Method, 2020-2027
9.3.1.3 Market size analysis, By Type of Waste, 2020-2027
9.3.1.4 Market size analysis, By Resorbability, 2020-2027
9.3.2 Japan
9.3.2.1 Market size analysis, By Lumen, 2020-2027
9.3.2.2 Market size analysis, By Method, 2020-2027
9.3.2.3 Market size analysis, By Type of Waste, 2020-2027
9.3.2.4 Market size analysis, By Resorbability, 2020-2027
9.3.3 India
9.3.3.1 Market size analysis, By Lumen, 2020-2027
9.3.3.2 Market size analysis, By Method, 2020-2027
9.3.3.3 Market size analysis, By Type of Waste, 2020-2027
9.3.3.4 Market size analysis, By Resorbability, 2020-2027
9.3.4 Australia
9.3.4.1 Market size analysis, By Lumen, 2020-2027
9.3.4.2 Market size analysis, By Method, 2020-2027
9.3.4.3 Market size analysis, By Type of Waste, 2020-2027
9.3.4.4 Market size analysis, By Resorbability, 2020-2027
9.3.5 South Korea
9.3.5.1 Market size analysis, By Lumen, 2020-2027
9.3.5.2 Market size analysis, By Method, 2020-2027
9.3.5.3 Market size analysis, By Type of Waste, 2020-2027
9.3.5.4 Market size analysis, By Resorbability, 2020-2027
9.3.6 Rest of Asia-Pacific
9.3.6.1 Market size analysis, By Lumen, 2020-2027
9.3.6.2 Market size analysis, By Method, 2020-2027
9.3.6.3 Market size analysis, By Type of Waste, 2020-2027
9.3.6.4 Market size analysis, By Resorbability, 2020-2027
9.3.7 Research Dive Exclusive Insights
9.3.7.1 Market attractiveness
9.3.7.2 Competition heatmap
9.4 LAMEA
9.4.1 Brazil
9.4.1.1 Market size analysis, By Lumen, 2020-2027
9.4.1.2 Market size analysis, By Method, 2020-2027
9.4.1.3 Market size analysis, By Type of Waste, 2020-2027
9.4.1.4 Market size analysis, By Resorbability, 2020-2027
9.4.2 Saudi Arabia
9.4.2.1 Market size analysis, By Lumen, 2020-2027
9.4.2.2 Market size analysis, By Method, 2020-2027
9.4.2.3 Market size analysis, By Type of Waste, 2020-2027
9.4.2.4 Market size analysis, By Resorbability, 2020-2027
9.4.3 UAE
9.4.3.1 Market size analysis, By Lumen, 2020-2027
9.4.3.2 Market size analysis, By Method, 2020-2027
9.4.3.3 Market size analysis, By Type of Waste, 2020-2027
9.4.3.4 Market size analysis, By Resorbability, 2020-2027
9.4.4 South Africa
9.4.4.1 Market size analysis, By Lumen, 2020-2027
9.4.4.2 Market size analysis, By Method, 2020-2027
9.4.4.3 Market size analysis, By Type of Waste, 2020-2027
9.4.4.4 Market size analysis, By Resorbability, 2020-2027
9.4.5 Rest of LAMEA
9.4.5.1 Market size analysis, By Lumen, 2020-2027
9.4.5.2 Market size analysis, By Method, 2020-2027
9.4.5.3 Market size analysis, By Type of Waste, 2020-2027
9.4.5.4 Market size analysis, By Resorbability, 2020-2027
9.4.6 Research Dive Exclusive Insights
9.4.6.1 Market attractiveness
9.4.6.2 Competition heatmap
10. Competitive Landscape
10.1 Top winning strategies, 2020-2027
10.1.1 By strategy
10.1.2 By year
10.2 Strategic overview
10.3 Market share analysis, 2020-2027
11. Company Profiles
11.1 llumina, Inc.
11.1.1 Overview
11.1.2 Business segments
11.1.3 Product portfolio
11.1.4 Financial performance
11.1.5 Recent developments
11.1.6 SWOT analysis
11.2 QIAGEN N.V.
11.2.1 Overview
11.2.2 Business segments
11.2.3 Product portfolio
11.2.4 Financial performance
11.2.5 Recent developments
11.2.6 SWOT analysis
11.3 NeoGenomics Laboratories, Inc.
11.3.1 Overview
11.3.2 Business segments
11.3.3 Product portfolio
11.3.4 Financial performance
11.3.5 Recent developments
11.3.6 SWOT analysis
11.4 HTG Molecular Diagnostics, Inc.
11.4.1 Overview
11.4.2 Business segments
11.4.3 Product portfolio
11.4.4 Financial performance
11.4.5 Recent developments
11.4.6 SWOT analysis
11.5 Genomic Health Inc.
11.5.1 Overview
11.5.2 Business segments
11.5.3 Product portfolio
11.5.4 Financial performance
11.5.5 Recent developments
11.5.6 SWOT analysis
11.6 Caris Life Sciences
11.6.1 Overview
11.6.2 Business segments
11.6.3 Product portfolio
11.6.4 Financial performance
11.6.5 Recent developments
11.6.6 SWOT analysis
11.7 Helomics Corporation
11.7.1 Overview
11.7.2 Business segments
11.7.3 Product portfolio
11.7.4 Financial performance
11.7.5 Recent developments
11.7.6 SWOT analysis
11.8 NanoString Technologies, Inc.
11.8.1 Overview
11.8.2 Business segments
11.8.3 Product portfolio
11.8.4 Financial performance
11.8.5 Recent developments
11.8.6 SWOT analysis
11.9 Sysmex Corporation
11.9.1 Overview
11.9.2 Business segments
11.9.3 Product portfolio
11.9.4 Financial performance
11.9.5 Recent developments
11.9.6 SWOT analysis
11.10 Ribomed Biotechnologies, Inc.
11.10.1 Overview
11.10.2 Business segments
11.10.3 Product portfolio
11.10.4 Financial performance
11.10.5 Recent developments
11.10.6 SWOT analysis
11.11 Guardant Health, Inc.
11.11.1 Overview
11.11.2 Business segments
11.11.3 Product portfolio
11.11.4 Financial performance
11.11.5 Recent developments
11.11.6 SWOT analysis
11.12 Foundation Medicine
11.12.1 Overview
11.12.2 Business segments
11.12.3 Product portfolio
11.12.4 Financial performance
11.12.5 Recent developments
11.12.6 SWOT analysis
11.13 Roche Diagnostics
11.13.1 Overview
11.13.2 Business segments
11.13.3 Product portfolio
11.13.4 Financial performance
11.13.5 Recent developments
11.13.6 SWOT analysis
11.14 GenScript Biotech Corporation
11.14.1 Overview
11.14.2 Business segments
11.14.3 Product portfolio
11.14.4 Financial performance
11.14.5 Recent developments
11.14.6 SWOT analysis
11.15 Tempus Labs
11.15.1 Overview
11.15.2 Business segments
11.15.3 Product portfolio
11.15.4 Financial performance
11.15.5 Recent developments
11.15.6 SWOT analysis
11.16 Boreal Genomics Inc
11.16.1 Overview
11.16.2 Business segments
11.16.3 Product portfolio
11.16.4 Financial performance
11.16.5 Recent developments
11.16.6 SWOT analysis
11.17 Perthera
11.17.1 Overview
11.17.2 Business segments
11.17.3 Product portfolio
11.17.4 Financial performance
11.17.5 Recent developments
11.17.6 SWOT analysis
11.18 Agendia
11.18.1 Overview
11.18.2 Business segments
11.18.3 Product portfolio
11.18.4 Financial performance
11.18.5 Recent developments
11.18.6 SWOT analysis
11.19 Omniseq
11.19.1 Overview
11.19.2 Business segments
11.19.3 Product portfolio
11.19.4 Financial performance
11.19.5 Recent developments
11.19.6 SWOT analysis
11.20 Histogene X
11.20.1 Overview
11.20.2 Business segments
11.20.3 Product portfolio
11.20.4 Financial performance
11.20.5 Recent developments
11.20.6 SWOT analysis
Personalize this research
- Triangulate with your own data
- Request your format and definition
- Get a deeper dive on a specific application, geography, customer or competitor
- + 1-888-961-4454 Toll - Free
- support@researchdive.com
